Capital Planning Advisors LLC Buys New Position in Boston Scientific Corporation $BSX

Capital Planning Advisors LLC purchased a new position in Boston Scientific Corporation (NYSE:BSX) in the third quarter, HoldingsChannel.com reports. The firm purchased 14,864 shares of the medical equipment provider’s stock, valued at approximately $1,451,000.

A number of other hedge funds also recently made changes to their positions in BSX. Steph & Co. purchased a new position in shares of Boston Scientific in the third quarter valued at $25,000. Financial Consulate Inc. purchased a new position in Boston Scientific in the 3rd quarter valued at about $25,000. Murphy & Mullick Capital Management Corp grew its stake in shares of Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 170 shares in the last quarter. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific during the second quarter worth about $26,000. Finally, United Community Bank lifted its stake in shares of Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.8%

BSX stock opened at $74.72 on Monday. The firm has a market cap of $110.76 billion, a price-to-earnings ratio of 38.51, a PEG ratio of 1.03 and a beta of 0.67. Boston Scientific Corporation has a 1-year low of $72.69 and a 1-year high of $109.50. The firm has a fifty day moving average price of $90.93 and a two-hundred day moving average price of $97.56. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.96%. The business had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. The company’s quarterly revenue was up 15.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BSX. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Robert W. Baird dropped their price target on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. JPMorgan Chase & Co. cut their price target on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Canaccord Genuity Group decreased their price objective on shares of Boston Scientific from $131.00 to $112.00 and set a “buy” rating for the company in a report on Thursday, February 5th. Finally, National Bank Financial set a $115.00 target price on shares of Boston Scientific in a research note on Monday, February 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and an average target price of $109.43.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.